Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing
News originally published by
GlobeNewswireNorth America Holds 42% of a USD 1.88 Trillion Market, Prescription Drugs 87% and Cancer 19%, While Biologics and Obesity Grow Fastest: Precedence Research Segment, Company and Buyer Intelligence
Ottawa, Nov. 18, 2026 (GLOBE NEWSWIRE) -- 
The global pharmaceutical market is valued at USD 1.88 trillion in 2026, up from USD 1.77 trillion in 2025, and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. The U.S. market is expected to grow from USD 552.72 billion in 2026 to about USD 963.52 billion by 2035.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Precedence Research today released updated intelligence on the global pharmaceutical market, covering prescription and over-the-counter medicines, small molecules, biologics and biosimilars, and the companies, channels and policies that shape them. The market is valued at USD 1.88 trillion in 2026 and is forecast to reach USD 3.20 trillion by 2035, adding about USD 1.32 trillion in annual sales.
Growth is concentrated in a few therapy areas. Obesity is the fastest-growing disease area, oncology is the largest with 19% of revenue, and immunology continues to expand. Company results show the same pattern: Eli Lilly's third-quarter 2026 revenue rose 39% to USD 24.4 billion on the strength of Mounjaro and Zepbound, AstraZeneca's oncology sales grew 16% in the first nine months, and Roche's pharmaceuticals division grew 7% at constant exchange rates.
Policy is reshaping the industry at the same time. On April 2, 2026, the U.S. imposed Section 232 tariffs of up to 100% on imported patented drugs, with a 0% rate through January 2029 for companies that sign most-favored-nation (MFN) pricing agreements and commit to U.S. manufacturing. The administration links about USD 400 billion of U.S. manufacturing commitments to the policy. For drugmakers, generic producers, CDMOs, distributors, payers and investors, pricing, location of production and pipeline renewal are now the central strategic questions.
Full report: https://www.precedenceresearch.com/pharmaceutical-market
Request a sample: https://www.precedenceresearch.com/sample/6227

Figure 1: Pharmaceutical Market Snapshot
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
The market grows steadily rather than explosively because strong growth in new medicines is partly offset by patent expiries, generic and biosimilar competition, and price controls. Net growth therefore depends on how quickly companies replace older revenue with new launches.
Segment Intelligence: Dominant and Fastest-Growing Segments
2026 values apply the published 2025 shares to the 2026 market size of USD 1.88 trillion and are modeled estimates.
Pharmaceutical Market: Key Segments
| Segment | 2025 Share | 2026 Value (modeled) | Growth Signal | |
| Prescription drugs | 87 | % | About USD 1,636 billion | Largest type; OTC grows fastest |
| Branded products | 87 | % | About USD 1,636 billion | Largest; generics grow fastest |
| Conventional small molecules | 55 | % | About USD 1,034 billion | Largest; biologics and biosimilars grow fastest |
| Cancer (disease area) | 19 | % | About USD 357 billion | Largest disease area; obesity grows fastest |
| Oral (route) | 58 | % | About USD 1,090 billion | Largest route; parenteral grows significantly |
| Adults (age group) | 64 | % | About USD 1,203 billion | Largest; geriatric grows fastest |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Type and product. Prescription and branded medicines dominate revenue. Over-the-counter drugs and generic drugs grow fastest as patents expire and consumers self-treat more conditions.
Molecule and disease. Small molecules still account for 55% of revenue, but biologics and biosimilars grow fastest. Cancer is the largest disease area, while obesity is the fastest-growing, driven by GLP-1 medicines.
Channel. Hospital pharmacies are the largest channel, and retail pharmacies grow fastest as more specialty and chronic-care drugs move into community settings.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Regional and Country Analysis
Pharmaceutical Market by Region
| Region | Position | Key Facts | Growth Signal |
| North America | Largest, 42% (2025) | U.S. USD 552.72B (2026) → about USD 963.52B (2035) | Tariffs and MFN pricing reshape supply |
| Europe | Major market and producer | Home to Roche, Novartis, Sanofi, GSK, Novo Nordisk | Exports to the U.S. affected by tariffs |
| Asia Pacific | Fastest-growing | China and India manufacturing; Japan innovation | Rising access and local innovation |
| Latin America and MEA | Emerging | Brazil, Mexico, Gulf states | Expanding coverage |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
North America. The U.S. is the largest and most profitable market. The April 2026 Section 232 proclamation applies tariffs of up to 100% on imported patented drugs and ingredients, while companies that sign MFN pricing agreements and onshore production qualify for a 0% rate through January 20, 2029. Tariffs took effect on July 31, 2026, for 17 large manufacturers, and nine more companies, including Sun Pharma, Teva, CSL, Astellas and BeOne Medicines, signed MFN agreements on August 31, 2026, with USD 19.6 billion of U.S. manufacturing commitments.
Europe. Europe is both a major market and the largest exporter of medicines to the U.S. Roche reported nine-month 2026 pharmaceuticals sales of CHF 36.2 billion, up 7% at constant exchange rates, with Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo together growing 12%.
Asia Pacific. Asia Pacific is the fastest-growing region. China is a major source of new drug candidates licensed by Western companies, India is the largest supplier of generic medicines, and Japan's Daiichi Sankyo and Takeda are major innovators.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
What Is Changing in the Industry

Figure 2: Policy and Company Milestones Reshaping Pharma, 2025–2026
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
U.S. pricing and tariffs are now linked. Thirteen drugmakers signed MFN pricing deals in late 2025, and the April 2026 tariff proclamation made such deals, combined with U.S. manufacturing commitments, the route to a 0% tariff. Pfizer says its agreements lock in a 0% tariff into early 2029.
What it indicates: Lower U.S. net prices and higher U.S. manufacturing investment will reshape margins and supply chains through the end of the decade.
Obesity and oncology are driving industry growth. Lilly's Mounjaro reached USD 10.7 billion and Zepbound USD 5.4 billion in the third quarter of 2026. AstraZeneca's oncology revenue reached USD 21.9 billion in the first nine months, 47% of its total.
What it indicates: Companies with leading positions in GLP-1 medicines and cancer therapies are growing far faster than the market.
Older franchises are under pressure. Pfizer's third-quarter revenue was flat at USD 16.6 billion as COVID-19 products declined, although non-COVID products grew 7% and launched and acquired products grew 32%. Roche continues to offset biosimilar erosion with newer medicines.
What it indicates: Replacing revenue lost to patent expiries and falling COVID demand is the central challenge for many large drugmakers.
Deals are refilling pipelines. GSK agreed to buy Nuvalent for USD 10.6 billion, Pfizer signed a collaboration with Innovent worth up to USD 10.5 billion, and Sun Pharma agreed to acquire Organon for USD 11.75 billion in 2026.
What it indicates: M&A and licensing, especially of Chinese assets, will remain a major source of growth.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Key Market Drivers
- Rising chronic disease, obesity and cancer, and an aging population.
- Innovation in biologics, cell and gene therapy and targeted cancer drugs.
- Use of AI in drug discovery and clinical trials.
- Expanding access in Asia Pacific and emerging markets.
-
Growth of telehealth and digital health channels.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Major Challenges
- Patent expiries and biosimilar competition.
- U.S. MFN pricing, Medicare negotiation and 340B changes.
- Tariffs and supply chain relocation costs.
- High R&D costs and late-stage failures.
- Price controls and reimbursement pressure in Europe and China.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Emerging Opportunities
- Obesity, the fastest-growing disease area.
- Biologics and biosimilars, the fastest-growing molecule types.
- Generics and OTC, the fastest-growing product and type segments.
- U.S. manufacturing and active pharmaceutical ingredient supply under new tariff rules.
-
Geriatric medicine, the fastest-growing age group.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Company and Competitive Intelligence

Figure 3: Leading Drugmakers, Third-Quarter 2026 Revenue
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
The industry is led by large innovative drugmakers, with Eli Lilly now the fastest-growing major company. Other leaders include Johnson & Johnson, Roche, Merck & Co., Pfizer, AstraZeneca, Novartis, AbbVie, Novo Nordisk and Sanofi. Generic and biosimilar producers such as Teva, Sandoz, Viatris and Sun Pharma serve the high-volume end of the market.
| Company | Latest Reported Data | Growth Drivers | Strategic Direction |
| Eli Lilly | Q3 2026 revenue USD 24.4B (+39%); 2026 guide USD 91–92B | Mounjaro, Zepbound, Foundayo | USD 50B U.S. manufacturing; obesity pipeline |
| Merck & Co. | Q3 2026 revenue USD 18.1B; Keytruda USD 8.6B | Keytruda, Keytruda Qlex, Gardasil | Terns deal; replace Keytruda before 2028 |
| Pfizer | Q3 2026 revenue USD 16.6B; 2026 guide raised to USD 62–64B | Launched and acquired products +32% | Innovent and Metsera deals; MFN agreement |
| AstraZeneca | Q3 2026 revenue USD 16.2B (+7%); oncology 9M USD 21.9B (+16%) | Tagrisso, Imfinzi, Enhertu | Oncology and ADCs |
| Roche | 9M 2026 pharma sales CHF 36.2B (+7% CER) | Xolair, Hemlibra, Ocrevus, Vabysmo | Pipeline prioritization; Hansoh deal |
| Novartis | Q3 2026 sales USD 14.52B (+4%) | Pluvicto, Kisqali | Radioligand therapy investment |
| Amgen / Gilead | Q3 2026 revenue USD 10.4B (+8%) / USD 8.3B (+7%) | Repatha, Imdelltra / HIV +18% | MariTide; four Gilead acquisitions |
| Sun Pharma / Teva | MFN agreements (Aug 2026) | Generics and specialty | U.S. manufacturing commitments |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Customer and Buyer Intelligence
| Target Account Group | Decision-Makers | Purchase Signals | Commercial Opportunity |
| Hospitals and health systems | Chief Pharmacy Officer, P&T Committee | New launches, budget reviews | Formulary and supply contracts |
| Payers and PBMs | Pharmacy Director, Medical Director | MFN prices, biosimilar entry | Value-based and rebate contracts |
| Pharma business development | Head of BD, R&D Head | Patent expiries, pipeline gaps | Licensing and M&A |
| CDMOs and API suppliers | BD and Operations Heads | Onshoring plans | U.S. manufacturing capacity |
| Distributors and pharmacies | Category and Procurement Heads | Generic launches, specialty growth | Distribution and specialty services |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
How Precedence Research Supports Decision-Making
Master Dataset provides segment, regional and company data for pharmaceuticals and adjacent markets such as the U.S. pharmaceutical, biologics and generic drugs markets. It helps teams size demand by type, molecule, disease, route and channel.
Precedence Quadrant compares drugmakers on growth, pipeline strength, patent exposure and manufacturing footprint, helping partners and investors benchmark leaders.
Interactive Intelligence Dashboard tracks results, approvals, deals, pricing agreements and tariff decisions, so commercial and strategy teams can respond quickly.
Quality & Manufacturing Intelligence maps API, CDMO and finished-dose capacity by country, supporting onshoring and sourcing decisions.
Customized Research answers specific questions, such as the impact of MFN pricing on a portfolio, tariff exposure by product or opportunities in obesity and oncology.
| Solution | What It Provides | How It Helps |
| Master Dataset | Segment, region and company data on pharmaceuticals | Sizes demand by disease and product |
| Precedence Quadrant | Drugmaker comparison on growth and pipeline | Benchmarks leaders and partners |
| Interactive Dashboard | Live tracking of results, deals and policy | Times pricing and investment moves |
| Quality & Manufacturing Intelligence | API, CDMO and plant capacity mapping | Supports onshoring and sourcing |
| Customized Research | Pricing, tariff and therapy-area studies | Answers decision-specific questions |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Why Continuously Updated Intelligence Matters
Pharmaceutical pricing, trade and pipeline news now changes month to month. Monthly updates suit teams tracking tariff and MFN decisions and new approvals. Quarterly updates match company earnings. Six-monthly updates help strategy teams follow policy and patent timelines, and annual updates support investors reviewing market size and share. Precedence Research offers all four update cycles.
Strategic Outlook
- CEOs and CXOs: the market adds about USD 1.32 trillion by 2035; obesity, oncology and immunology will deliver most of it.
- Strategy and business development teams: licensing and M&A remain the fastest way to replace revenue lost to patent expiries.
- R&D leaders: biologics, biosimilars and obesity medicines are the fastest-growing areas.
- Procurement and supply teams: plan for U.S. onshoring and API sourcing under the new tariff rules.
- Investors: companies with MFN agreements, strong pipelines and U.S. capacity are best positioned.
- Manufacturers and CDMOs: about USD 400 billion of U.S. manufacturing commitments create demand for capacity and services.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Company Ecosystem

Figure 4: Pharma Leaders, Key 2026 Signals
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Figure 5: Pharmaceutical Company Ecosystem, 2026
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Call to Action
To understand how pricing, tariffs and pipelines will shape the pharmaceutical market through 2035, explore the full report or speak with a Precedence Research analyst.
- Report: https://www.precedenceresearch.com/pharmaceutical-market
- Request a sample: https://www.precedenceresearch.com/sample/6227
-
Schedule a meeting: https://www.precedenceresearch.com/schedule-meeting
Fill out the form for relevant samples, case studies, and examples. sales@precedenceresearch.com
Related Reports
- U.S. Pharmaceutical Market: https://www.precedenceresearch.com/us-pharmaceutical-market
- Biologics Market: https://www.precedenceresearch.com/biologics-market
- Biosimilars Market: https://www.precedenceresearch.com/biosimilars-market
- Generic Drugs Market: https://www.precedenceresearch.com/generic-drugs-market
- Over the Counter Drugs Market: https://www.precedenceresearch.com/over-the-counter-drugs-market
- Active Pharmaceutical Ingredient Market: https://www.precedenceresearch.com/active-pharmaceutical-ingredient-market
- Pharma 4.0 Market: https://www.precedenceresearch.com/pharma-4-0-market
- Pharmaceutical Analytical Testing Market: https://www.precedenceresearch.com/pharmaceutical-analytical-testing-market
- Pharmaceutical Water Market: https://www.precedenceresearch.com/pharmaceutical-water-market
- Artificial Intelligence in Drug Discovery Market: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market
- AI in Clinical Trials Market: https://www.precedenceresearch.com/ai-in-clinical-trials-market
- Oncology Clinical Trials Market: https://www.precedenceresearch.com/oncology-clinical-trials-market
- Clinical Trials Market: https://www.precedenceresearch.com/clinical-trials-market
- Drug Discovery Market: https://www.precedenceresearch.com/drug-discovery-market
- Cell and Gene Therapy Market: https://www.precedenceresearch.com/cell-and-gene-therapy-market
- Vaccines Market: https://www.precedenceresearch.com/vaccines-market
- Personalized Medicine Market: https://www.precedenceresearch.com/personalized-medicine-market
- Digital Health Market: https://www.precedenceresearch.com/digital-health-market
- Telehealth Market: https://www.precedenceresearch.com/telehealth-market
- Pharmacy Market: https://www.precedenceresearch.com/pharmacy-market
About Precedence Research
Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, ICT, energy, chemicals and materials, aerospace and other industries, helping executives and investors make evidence-based decisions.
Our Partners
- Towards Healthcare: https://www.towardshealthcare.com/
- Towards Packaging: https://www.towardspackaging.com/
- Towards Chemical & Materials: https://www.towardschemandmaterials.com/
Connect With Us
- USA: +1 804 441 9344
- APAC: +61 485 981 310 or +91 87933 22019
- Singapore: +65 3105 1271
- Europe: +44 7383 092 044
- Email: sales@precedenceresearch.com
Social Media
- LinkedIn: https://www.linkedin.com/company/precedence-research
- Facebook: https://www.facebook.com/precedenceresearch
- X: https://x.com/precedence_r
- Medium: https://precedence-research.medium.com/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
